Infliximab Biosimilar – Anti-TNF-alpha mAb – Research Grade

Reference:
Size

,

Isotype

IgG1

Brand

Product type

Clonality

Expression system

Applications

, ,

Product nameInfliximab Biosimilar - Anti-TNF-alpha mAb - Research Grade
SourceDrugBank DB00065
SpeciesHuman
Expression systemMammalian
Molecular weight144kDa
Purity>85%
BufferPBS pH7.5
Delivery conditionBlue ice (+4°C)
Delivery lead time in business days3-5 days if in stock; 3-5 weeks if production needed
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
Aliases /SynonymsInfliximab,Infliximab,TNF-alpha,anti-TNF-alpha
ReferencePX-TA1009
NoteFor research use only. Not suitable for human use.
IsotypeIgG1
ClonalityMonoclonal Antibody

Description of Infliximab Biosimilar - Anti-TNF-alpha mAb - Research Grade

General information about Infliximab

Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases. This includes Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease. It is given by slow injection into a vein, typically at six- to eight-week intervals. Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are monoclonal antibodies and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a “chimeric monoclonal antibody”. This product is for research use only.

Infliximab Biosimilar - Anti-TNF-alpha mAb binds to Human TNFa/TNF-alpha in indirect ELISA Assay

Immobilized Human TNFa Recombinant Protein (cat. No. PX-P3058) at 0.5µg/mL (100µL/well) can bind Infliximab Biosimilar - Anti-TNF-alpha mAb (cat. No. PX-TA1009) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 60.68M.

SDS-PAGE for Infliximab Biosimilar - Anti-TNF-alpha mAb

Infliximab Biosimilar - Anti-TNF-alpha mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

SPR results for Infliximab Biosimilar - Anti-TNF-alpha mAb and Human TNFa/TNF-alpha

Human TNFa Recombinant Protein (cat. No. PX-P3058) and Infliximab Biosimilar - Anti-TNF-alpha mAb (cat. No. PX-TA1009) were injected in OpenSPR giving a KD of 3.26E-09.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Infliximab Biosimilar – Anti-TNF-alpha mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Related products

Tumor necrosis factor(TNF)
Antigen

Tumor necrosis factor(TNF)

PX-P4641 250$
TNFa / TNF-alpha, N-His, recombinant protein (E.coli)
Antigen

TNFa / TNF-alpha, N-His, recombinant protein (E.coli)

PX-P5960 458$
Mouse TNFa / TNF-alpha, N-His, recombinant protein
Antigen

Mouse TNFa / TNF-alpha, N-His, recombinant protein

PX-P5992 458$
Human IgG1 LALA Isotype Control antibody (HyHEL-10)
Isotype Control

Human IgG1 LALA Isotype Control antibody (HyHEL-10)

PTX17885 214$
Anti-Infliximab Polyclonal Antibody
Polyclonal Antibody

Anti-Infliximab Polyclonal Antibody

PTX18865 774$
Infliximab ELISA Kit
ELISA

Infliximab ELISA Kit

KPTX130 1547$

Contact us

Send us a message from the form below







    Cart (0 Items)

    Your cart is currently empty.

    View Products